Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen CEO Steps Down After Quarterly Earnings Miss
10:16am, Tuesday, 03'rd May 2022
Biogen Inc (NASDAQ:BIIB) stepped into the earnings confessional today to post first-quarter earnings of $3.62 per share -- lower than the $4.38 per share analysts anticipated -- due to Alzheimer's
Biogen CEO Stepping Down After Struggles With Alzheimer's Drug Aduhelm
10:08am, Tuesday, 03'rd May 2022
The company said it will substantially eliminate the sales infrastructure related to Aduhelm, which is intended to provide savings of $1 billion annually when combined with other cost reductions.
Biogen Inc. (BIIB) Q1 Earnings Miss Estimates
09:47am, Tuesday, 03'rd May 2022
Biogen Inc. (BIIB) delivered earnings and revenue surprises of -17.91% and 1.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Biogen CEO Michel Vounatsos to step down following troubled Alzheimer's drug launch
09:31am, Tuesday, 03'rd May 2022
CNBC's Meg Tirrell joins 'Squawk Box' to report that Biogen CEO Michel Vounatsos will step down amid the company's troubled launch of its historic Alzheimer's drug Aduhelm.
Biogen CEO Michel Vounatsos to step down
07:48am, Tuesday, 03'rd May 2022
Biogen Inc. BIIB, -0.06% said Tuesday that it is conducting a search to replace CEO Michel Vounatsos, who will stay in his role unless a successor is named. The announcement was made in the company's
Biogen'a Q1 profit and revenue lag estimates, weighed down by Alzheimer's drug
07:35am, Tuesday, 03'rd May 2022
Shares of Biogen Inc. BIIB, -0.06% fell 2.3% in premarket trading on Tuesday after the company missed Wall Street's expectations for revenue and earnings for the first quarter of 2022. Biogen had net
Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More
07:55pm, Monday, 02'nd May 2022 Zacks Investment Research
Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.
Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More
05:18pm, Monday, 02'nd May 2022
Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.
The Zacks Analyst Blog Highlights Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen
10:22am, Monday, 02'nd May 2022 Zacks Investment Research
Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen have been included in this Analyst Blog.
Sage, Biogen start 'rolling submission' to FDA for depression drug
07:52am, Monday, 02'nd May 2022
Sage Therapeutics Inc. SAGE, -2.78% and Biogen Inc. BIIB, -1.41% said Monday that they started a rolling submission to the Food and Drug Administration for zuranolone, a treatment they are developing
Pfizer (PFE) to Report Q1 Earnings: What's in the Cards?
03:56pm, Friday, 29'th Apr 2022 Zacks Investment Research
Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the first quarter.
Biopharma can perform well in recession based on past data, says Wells Fargo's Mohit Bansal
03:22pm, Friday, 29'th Apr 2022
Mohit Bansal, Wells Fargo Securities senior equity analyst, joins 'Power Lunch' to discuss biopharma and the market.
AbbVie (ABBV) Q1 Earnings Top, Competition Rises for Imbruvica
03:20pm, Friday, 29'th Apr 2022 Zacks Investment Research
AbbVie (ABBV) beats estimates for first-quarter 2022 earnings while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares decline.
5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates
09:11am, Friday, 29'th Apr 2022
Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.
Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know
09:50pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Biogen Inc. (BIIB) closed at $210.41 in the latest trading session, marking a +1.68% move from the prior day.
